Avasopasem manganese is a Small Molecule owned by Galera Therapeutics, and is involved in 14 clinical trials, of which 13 were completed, and 1 is ongoing.

Avasopasem manganese is a MnSOD (dismutase mimetic) which exactly replicates the enzymatic rate and specificity of the native human enzyme. Like the enzyme it is completely selective for the dismutation of superoxide to hydrogen peroxide and inactive with respect to other oxygen species, allowing for targeted and controlled intervention in tumors and normal tissue. Unlike exogenous enzyme, as a small molecule, it is able to enter the intracellular sites where native MnSOD is typically found. As it has been shown with both gene transfection or overexpression and exogenous enzyme, GC-4419 disrupts tumor metabolism and microenvironment, attacking tumors alone and in combination with other cancer therapies. Likewise, it protects normal tissue such as oral mucosa from other therapies.

The revenue for Avasopasem manganese is expected to reach a total of $4.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Avasopasem manganese NPV Report.

Avasopasem manganese was originated by Kereos and is currently owned by Galera Therapeutics.

Avasopasem manganese Overview

Avasopasem manganese is under development for the treatment of cancer and head and neck squamous cell carcinoma, locally advanced pancreatic adenocarcinoma, radiation-induced esophagitis in patients with lung cancer. It is administered by intravenous infusion route. It is a small molecule enzyme mimetic that both attacks tumors and protects normal tissues from other cancer therapies. It mimics the activity of superoxide dismutase. The drug candidate was also under development for the treatment of arthritis.

It was under development for radiation-chemotherapy-induced oral mucositis in head and neck cancer patients

It was under development for the treatment of Coronavirus Disease 2019 (COVID-19).

Galera Therapeutics Overview

Galera Therapeutics (Galera) is a clinical-stage biotechnology company. It focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its pipeline portfolio includes Avasopasem (GC4419), Rucosopasem (GC4711), clinical trials and key publications. Galera GC4419 is a small molecule enzyme mimetic that quickly converts superoxide-free radical molecules to hydrogen peroxide and oxygen which reduces the incidence, severity, and duration of severe oral mucositis. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

The operating loss of the company was US$73.4 million in FY2021, compared to an operating loss of US$70.6 million in FY2020. The net loss of the company was US$80.5 million in FY2021, compared to a net loss of US$74.2 million in FY2020.

Quick View – Avasopasem manganese

Report Segments
  • Innovator
Drug Name
  • Avasopasem manganese
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.